Iranian Red Crescent Medical Journal

Published by: Kowsar

Prolonged Survival of a Patient With Pelvic Recurrence of Ovarian Malignant Mixed Mullerian Tumor After Chemoradiotherapy

Fatemeh Homaei Shandiz 1 , Sima Kadkhodayan 2 , * , Malihe Hsanzade Mofrad 2 , Zohre Yousefi Roodsari 2 , Noorieh Sharifi Sistani 1 , Majid Nabizadeh Marvast 3 and Mahbobe Sadeghei 1
Authors Information
1 Research Center of Solid Tumor Treatment, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran
2 Research Center of Women’s Health, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran
3 Mashhad University of Medical Sciences, Mashhad, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: September 01, 2014, 16 (9); e14919
  • Published Online: September 5, 2014
  • Article Type: Case Report
  • Received: September 18, 2013
  • Revised: April 27, 2014
  • Accepted: July 13, 2014
  • DOI: 10.5812/ircmj.14919

To Cite: Homaei Shandiz F, Kadkhodayan S, Hsanzade Mofrad M, Yousefi Roodsari Z, Sharifi Sistani N, et al. Prolonged Survival of a Patient With Pelvic Recurrence of Ovarian Malignant Mixed Mullerian Tumor After Chemoradiotherapy, Iran Red Crescent Med J. 2014 ; 16(9):e14919. doi: 10.5812/ircmj.14919.

Abstract
Copyright © 2014, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
Acknowledgements
Footnotes
References
  • 1. Duman BB, Kara IO, Gunaldi M, Ercolak V. Malignant mixed Mullerian tumor of the ovary with two cases and review of the literature. Arch Gynecol Obstet. 2011; 283(6): 1363-8[DOI][PubMed]
  • 2. Arora P, Rao S, Khurana N, Talwar D, Tanwar R. Malignant mixed Mullerian tumor of broad ligament with synchronous ovarian and endometrial carcinoma: a rare association. J Cancer Res Ther. 2011; 7(1): 88-91[DOI][PubMed]
  • 3. Ma CJ, Yang SF, Huang CC, Chai CY, Cheng KI, Tsai EM, et al. Malignant mixed mullerian tumor of primary mesenteric origin associated with a synchronous ovarian cancer: case report and literature review. Eur J Gynaecol Oncol. 2008; 29(3): 289-93[PubMed]
  • 4. Nasser H, Morris RT, Fathallah L. Ovarian malignant mixed mullerian tumor with primitive neuroectodermal differentiation: case report with review of the literature. Pathol Res Pract. 2011; 207(3): 202-6[DOI][PubMed]
  • 5. FIGO . Announcement. Gyn Oncol J. 1986; 25(3): 383-5[DOI]
  • 6. Belbaraka R, Taleb A, Errihani H. A Rare Tumor of the Ovary: Carcinosarcoma. Med Case J. 2010; 1(2): 55-7
  • 7. Shah A, Rekhi B, Maheshwari A, Jambhekar NA. Low-grade Mullerian adenosarcoma with prominent decidualization, involving bilateral ovaries against a background of endometriosis: a diagnostic and treatment challenge. J Postgrad Med. 2013; 59(2): 149-52[DOI][PubMed]
  • 8. del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol. 2012; 125(1): 271-7[DOI][PubMed]
  • 9. George EM, Herzog TJ, Neugut AI, Lu YS, Burke WM, Lewin SN, et al. Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome. Gynecol Oncol. 2013; 131(1): 42-5[DOI][PubMed]
  • 10. Rutledge TL, Gold MA, McMeekin DS, Huh WK, Powell MA, Lewin SN, et al. Carcinosarcoma of the ovary-a case series. Gynecol Oncol. 2006; 100(1): 128-32[DOI][PubMed]
  • 11. Tate Thigpen J, Blessing JA, DeGeest K, Look KY, Homesley HD, Gynecologic Oncology G. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 93(2): 336-9[DOI][PubMed]
  • 12. Kanthan R, Senger JL. Uterine carcinosarcomas (malignant mixed mullerian tumours): a review with special emphasis on the controversies in management. Obstet Gynecol Int. 2011; 2011: 470795[DOI][PubMed]
  • 13. Thomakos N, Rodolakis A, Zagouri F, Zacharakis D, Sotiropoulou M, Akrivos N, et al. Serum CA 125, CA 15-3, CEA, and CA 19-9: a prognostic factor for uterine carcinosarcomas? Arch Gynecol Obstet. 2013; 287(1): 97-102[DOI][PubMed]
  • 14. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004; 58(3): 786-96[DOI][PubMed]
  • 15. Mano MS, Rosa DD, Azambuja E, Ismael G, Braga S, D'Hondt V, et al. Current management of ovarian carcinosarcoma. Int J Gynecol Cancer. 2007; 17(2): 316-24[DOI][PubMed]
  • 16. Menon S, Deodhar K, Rekhi B, Dhake R, Gupta S, Ghosh J, et al. Clinico-pathological spectrum of primary ovarian malignant mixed mullerian tumors (OMMMT) from a tertiary cancer institute: A series of 27 cases. Indian J Pathol Microbiol. 2013; 56(4): 365-71[DOI][PubMed]
  • 17. Peters WA, 3rd, Bagley CM, Smith MR. CA-125. Use as a tumor marker with mixed mesodermal tumors of the female genital tract. Cancer. 1986; 58(12): 2625-7[PubMed]
  • 18. Dictor M. Malignant mixed mesodermal tumor of the ovary: a report of 22 cases. Obstet Gynecol. 1985; 65(5): 720-4[PubMed]
  • 19. Sood AK, Sorosky JI, Gelder MS, Buller RE, Anderson B, Wilkinson EJ, et al. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Cancer. 1998; 82(9): 1731-7[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments